CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 46 enrolled
Drug / intervention
Cholecalciferoldrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00674154
NCT00674154Phase 3Completed
CompareCT.gov

Effect of Vitamin D Treatment in Primary Hyperparathyroidism

University of Aarhus·interventional·Posted May 7, 2008·Updated Nov 18, 2013

In Brief

A Phase 3 clinical trial evaluating Cholecalciferol for Vitamin D Deficiency and 2 related conditions. Completed, enrolled 46 participants across 1 site.

Detailed Summary

The primary aim of the study is to assess whether 6-months of vitamin D supplements can decrease PTH compared with placebo treatment in primary hyperparathyroidism.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsVitamin D Deficiency, Primary Hyperparathyroidism, Hypercalcemia
CountriesDenmark
Collaborators--

Timeline

Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 7, 2008
Enrollment StartMay 1, 2008
Primary CompletionAug 1, 2013
TodayJul 2, 2026
Enrollment to primary: 5.3 yearsPosted 18.2 years ago

Interventions

Cholecalciferoldrug

2800 IE daily in 52 weeks